Key facts
- RenaBio Therapeutics’s last known valuation is $10.0M (Apr 2024).
- It has raised $1.3M across 2 recorded rounds; the latest was Seed Round ($250K) in Feb 2025.
- Notable investors include ABI LAB.
- RenaBio Therapeutics has filed 2 Form Ds with the SEC since 2024, most recently Feb 2025 ($250K sold to 1 investors).
- Status: Privately Held (backing).
Investors
1Free account
See the evidence behind this price
- ·Post-money valuations for all 2 rounds
- ·The complete investor list — 1 names
- ·Watchlist + deal alerts for RenaBio Therapeutics
Create free account
No card required
Funding rounds
2 roundsAbout RenaBio Therapeutics
The company is currently operating in Stealth Mode.
- Sector
- Business Products and Services (B2B)
- HQ
- Natick, MA, United States
- Founded
- 2023
- Ownership
- Privately Held (backing)
PA Mark — not yet priced
RenaBio Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Pro members can request priority coverage with a 48-hour turnaround.
Recorded secondary trades
No prints on record
No secondary trades in RenaBio Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Pro members can request priority coverage with a 48-hour turnaround.
Institutional fund marks
No fund marks yet
No SEC-registered fund has reported a fair-value mark on RenaBio Therapeutics in its N-PORT filings yet. We sweep new filings monthly.
Pro members can request priority coverage with a 48-hour turnaround.